Pharmacokinetic equivalence study of nonsteroidal anti-inflammatory drug etoricoxib

被引:12
作者
Tjandrawinata, Raymond R. [1 ]
Setiawati, Arini [2 ]
Nofiarny, Dwi [1 ]
Susanto, Liana W. [1 ]
Setiawati, Effi [3 ]
机构
[1] Dexa Med Grp, Dexa Labs Biomol Sci Unit, Ind Selatan 5 Block PP 7,Jababeka Ind Estate 2, Cikarang 17550, West Java, Indonesia
[2] Univ Indonesia, Med Fac, Dept Pharmacol & Therapeut, Jakarta, Indonesia
[3] PT Equilab Int, Bioavailabil & Bioequivalence Lab Unit, Jakarta, Indonesia
关键词
bioavailability; bioequivalence; etoricoxib; nonsteroidal anti-inflammatory drug; selective cyclooxygenase-2 inhibitor;
D O I
10.2147/CPAA.S161024
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: The current study aimed to evaluate whether a generic product of etoricoxib 120 mg film-coated tablet (the test drug) was bioequivalent to the reference product (Arcoxia (R) film-coated tablet 120 mg). Methods: This was a randomized, open-label, two-sequence, crossover study under fasting condition, with a 14-day washout period, involving 26 healthy adult male and female subjects. Blood samples were taken and analyzed for plasma concentrations of etoricoxib (Chemical Abstracts Service [CAS] 202409-33-4) using a high-pressure liquid chromatography-ultraviolet detector (HPLC-UV) system capable of measuring etoricoxib concentrations ranging from 5.00 to 5002.90 ng/mL, with the lowest limit of quantitation of 5.00 ng/mL. A noncompartmental method was used to determine the pharmacokinetic parameters of a single-dose administration of the drug, including the area under plasma concentration-time curve from time zero to the time of last observed concentration (AUC(0-t)), the area under plasma concentration-time curve from time zero to infinity (AUC(0-infinity)), the maximum plasma concentration (C-max), the time to reach the maximum plasma concentration (t(max)), and the terminal half-life (t(1/2)). Results: After a single-dose administration of etoricoxib 120 mg film-coated tablet, the mean (SD) values for the AUC(0-72h) and C-max of the test drug were 45913.42 (13142.19) ng.h/mL and 3155.93 (752.81) ng/mL, respectively; the values for the reference drug were 44577.20 (13541.85) ng.h/mL and 2915.13 (772.81) ng/mL, respectively. The geometric mean ratios (90% CIs) of the test drug/reference drug were 103.40% (98.70%-108.32%) for AUC(0-72h) and 109.26% (100.18%-119.18%) for C-max. No clinically significant differences in t(max) and t(1/2) values were found between the test drug and the reference drug. No adverse events were experienced by the subjects during this study. Conclusion: The present study demonstrated that the evaluated generic etoricoxib 120 mg film-coated tablets were bioequivalent to the reference drug.
引用
收藏
页码:43 / 51
页数:9
相关论文
共 26 条
[1]  
[Anonymous], 2017, WPCMK0663T062015 MER
[2]   Pharmacoeconomics - an aid to better decision-making [J].
Arenas-Guzman, R ;
Tosti, A ;
Hay, R ;
Haneke, E .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2005, 19 :34-39
[3]  
BPOM. Badan Pengawas Obat dan Makanan Republik Indonesia, 2004, BAD PENG OB DAN MAK
[4]  
BPOM. Badan Pengawas Obat dan Makanan Republik Indonesia, 2011, BAD PENG OB DAN MAK
[5]   On sample size calculation in bioequivalence trials [J].
Chow, SC ;
Wang, HS .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2001, 28 (02) :155-169
[6]  
Danta M, 2017, J VIRUS ERAD, V3, P77
[7]  
Davit B., 2016, APPL BIOPHARMACEUTIC, P469
[8]  
DILETTI E, 1991, INT J CLIN PHARM TH, V29, P1
[9]  
Dixon W.J., 1969, INTRO STAT ANAL
[10]  
EMA, 2012, GEN HYBR MED